Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients

被引:74
作者
MacConaill, Laura E. [1 ,2 ]
Garcia, Elizabeth [1 ]
Shivdasani, Priyanka [1 ]
Ducar, Matthew [2 ]
Adusumilli, Ravali [2 ]
Breneiser, Marc [2 ]
Byrne, Mark [1 ]
Chung, Lawrence [1 ]
Conneely, Jodie [1 ]
Crosby, Lauren [1 ]
Garraway, Levi A. [2 ,3 ]
Gong, Xin [1 ]
Hahn, William C. [2 ,3 ]
Hatton, Charlie [2 ]
Kantoff, Philip W. [3 ]
Kluk, Michael [1 ]
Kuo, Frank [1 ]
Jia, Yonghui [1 ]
Joshi, Ruchi [1 ]
Longtine, Janina [1 ]
Manning, Allison [1 ]
Palescandolo, Emanuele [2 ]
Sharaf, Nematullah [1 ]
Sholl, Lynette [1 ]
van Hummelen, Paul [2 ]
Wade, Jacqueline [1 ]
Wollinson, Bruce M. [2 ]
Zepf, Dimity [1 ]
Rollins, Barrett J. [3 ]
Lindeman, Neal I. [1 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA USA
关键词
METASTATIC COLORECTAL-CANCER; BRAF MUTATIONS; GENE-MUTATIONS; SOMATIC MUTATIONS; LUNG-CANCER; LEUKEMIA; TUMORS; EGFR; RAS; CHEMOTHERAPY;
D O I
10.1016/j.jmoldx.2014.06.004
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Ongoing cancer genome characterization studies continue to elucidate the spectrum of genomic abnormalities that drive many cancers, and in the clinical arena assessment of the driver genetic alterations in patients is playing an increasingly important diagnostic and/or prognostic rote for many cancer types. However, the landscape of genomic abnormalities is still unknown for less common cancers, and the influence of specific genotypes on clinical behavior is often still unclear. To address some of these deficiencies, we developed Profile, a prospective cohort study to obtain genomic information on all patients at a large tertiary care medical center for cancer-related care. We enrolled patients with any cancer diagnosis, and, for each patient (unselected for cancer site or type) we applied mass spectrometric genotyping (OncoMap) of 471 common recurrent mutations in 41 cancer-related genes. We report the results of the first 5000 patients, of which 26% exhibited potentially actionable somatic mutations. These observations indicate the utility of genotyping in advancing the field of precision oncology.
引用
收藏
页码:660 / 672
页数:13
相关论文
共 62 条
[1]
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours [J].
Amary, M. Fernanda ;
Bacsi, Krisztian ;
Maggiani, Francesca ;
Damato, Stephen ;
Halai, Dina ;
Berisha, Fitim ;
Pollock, Robin ;
O'Donnell, Paul ;
Grigoriadis, Anita ;
Diss, Tim ;
Eskandarpour, Malihe ;
Presneau, Nadege ;
Hogendoorn, Pancras C. W. ;
Futreal, Andrew ;
Tirabosco, Roberto ;
Flanagan, Adrienne M. .
JOURNAL OF PATHOLOGY, 2011, 224 (03) :334-343
[2]
Arcila ME, 2011, MODERN PATHOL, V24, p404A
[3]
Detection of KRAS and BRAF Mutations in Colorectal Carcinoma Roles for High-Sensitivity Locked Nucleic Acid-PCR Sequencing and Broad-Spectrum Mass Spectrometry Genotyping [J].
Arcila, Maria ;
Lau, Christopher ;
Nafa, Khedoudja ;
Ladanyi, Marc .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2011, 13 (01) :64-73
[4]
Recurrent BRAF mutations in Langerhans cell histiocytosis [J].
Badalian-Very, Gayane ;
Vergilio, Jo-Anne ;
Degar, Barbara A. ;
MacConaill, Laura E. ;
Brandner, Barbara ;
Calicchio, Monica L. ;
Kuo, Frank C. ;
Ligon, Azra H. ;
Stevenson, Kristen E. ;
Kehoe, Sarah M. ;
Garraway, Levi A. ;
Hahn, William C. ;
Meyerson, Matthew ;
Fleming, Mark D. ;
Rollins, Barrett J. .
BLOOD, 2010, 116 (11) :1919-1923
[5]
Multiplex Mutation Screening by Mass Spectrometry Evaluation of 820 Cases from a Personalized Cancer Medicine Registry [J].
Beadling, Carol ;
Heinrich, Michael C. ;
Warrick, Andrea ;
Forbes, Erin M. ;
Nelson, Dylan ;
Justusson, Emily ;
Levine, Judith ;
Neff, Tanaya L. ;
Patterson, Janice ;
Presnell, Ajia ;
McKinley, Arin ;
Winter, Laura J. ;
Dewey, Christie ;
Harlow, Amy ;
Barney, Oscar ;
Druker, Brian J. ;
Schuff, Kathryn G. ;
Corless, Christopher L. .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2011, 13 (05) :504-513
[6]
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping [J].
Borger, Darrell R. ;
Tanabe, Kenneth K. ;
Fan, Kenneth C. ;
Lopez, Hector U. ;
Fantin, Valeria R. ;
Straley, Kimberly S. ;
Schenkein, David P. ;
Hezel, Aram F. ;
Ancukiewicz, Marek ;
Liebman, Hannah M. ;
Kwak, Eunice L. ;
Clark, Jeffrey W. ;
Ryan, David P. ;
Deshpande, Vikram ;
Dias-Santagata, Dora ;
Ellisen, Leif W. ;
Zhu, Andrew X. ;
Iafrate, A. John .
ONCOLOGIST, 2012, 17 (01) :72-79
[7]
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations [J].
Brastianos, Priscilla K. ;
Horowitz, Peleg M. ;
Santagata, Sandro ;
Jones, Robert T. ;
McKenna, Aaron ;
Getz, Gad ;
Ligon, Keith L. ;
Palescandolo, Emanuele ;
Van Hummelen, Paul ;
Ducar, Matthew D. ;
Raza, Alina ;
Sunkavalli, Ashwini ;
MacConaill, Laura E. ;
Stemmer-Rachamimov, Anat O. ;
Louis, David N. ;
Hahn, William C. ;
Dunn, Ian F. ;
Beroukhim, Rameen .
NATURE GENETICS, 2013, 45 (03) :285-289
[8]
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer [J].
Cadranel, J. ;
Zalcman, G. ;
Sequist, L. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (01) :183-193
[9]
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer [J].
Carpten, John D. ;
Faber, Andrew L. ;
Horn, Candice ;
Donoho, Gregory P. ;
Briggs, Stephen L. ;
Robbins, Christiane M. ;
Hostetter, Galen ;
Boguslawski, Sophie ;
Moses, Tracy Y. ;
Savage, Stephanie ;
Uhlik, Mark ;
Lin, Aimin ;
Du, Jian ;
Qian, Yue-Wei ;
Zeckner, Douglas J. ;
Tucker-Kellogg, Greg ;
Touchman, Jeffrey ;
Patel, Ketan ;
Mousses, Spyro ;
Bittner, Michael ;
Schevitz, Richard ;
Lai, Mei-Huei T. ;
Blanchard, Kerry L. ;
Thomas, James E. .
NATURE, 2007, 448 (7152) :439-U1
[10]
PTEN and the PI3-Kinase Pathway in Cancer [J].
Chalhoub, Nader ;
Baker, Suzanne J. .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2009, 4 :127-150